Biotech Company Reports Promising Neurological Treatment in Clinical Study
Clinical-stage biotechnology company Coya Therapeutics Inc. (COYA:NASDAQ) announces positive interim results of a study for the treatment of patients with frontotemporal dementia (FTD). Read to see what catalysts one analyst said the stock can look forward to this year.Biopharma Company Leverages AI-Powered Platform for Cancer Breakthroughs
Rakovina Therapeutics Inc. (RKV:TSX.V) announced its scientific advisor and collaborator Dr. Artem Cherkasov was recently recognized as a leader in AI-driven drug development. Find out which analysts recently initiated coverage on the company.Biotech Discovers Revolutionary Immunotherapy in Houston
Research Report
Coya Therapeutics Inc. (COYA:NASDAQ) recently reported a statistically significant Treg improvement in FTD patients with its dual-action immunotherapy, showing promising neuroprotection, according to a D. Boral research note. Analyst Reveals Undervalued Pharmaceutical Gem in Canada
Research Report
In a recent research note from Leede Financial Inc. analyst Dr. Douglas Loe said Theratechnologies Inc. (TH:TSX; THTX:NASDAQ) has long term potential. Four-Year Data on New Drug for Early AD Positive
Research Report
Long-term treatment with this small molecule seems feasible given its safety and tolerability profile, noted an H.C. Wainwright & Co. report. Rest of 2025 Rich With Catalysts for Immunotherapy Co.
Research Report
These anticipated events will advance the oncology firm's lead candidate, for lung-only metastatic osteosarcoma, toward commercialization, noted a D. Boral Capital report. New Drug for Early AD Shown to be Efficacious, Safe
Research Report
Trial participants exhibited improvements in cognitive function and activities of daily living, noted a D. Boral Capital report. Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal
Beam Therapeutics Inc. (BEAM:NASDAQ) shows strong momentum with positive analyst ratings and new data from its BEAM-302 trial in AATD. Find out why experts see major upside potential.New Therapy for AATD Could be Best in Class
Research Report
Updated trial data show it to be safe and efficacious and have a dual mechanism of action, noted an H.C. Wainwright & Co. report. Share Price Appreciation of Biotech Due Over Next Six Months
Research Report
Given its robust pipeline, numerous milestones for this Outperform-rated company are slated to occur in the near-term, noted a Wedbush report. Biotech Company Finds High-Impact Alzheimer's Therapy in Europe
Anavex Life Sciences Corp. (AVXL:NASDAQ) earned positive analyst coverage following new long-term data for blarcamesine in early Alzheimer's disease. Experts pointed to safety, durability, and potential approval pathways. Read more about what they said.Immunotherapy Company Finds Rare Cancer Breakthrough in U.S.
OS Therapies Inc. (OSTX:NYSEAMERICAN) announced that its lead drug OST-HER2 was granted Orphan Drug Designation by the FDA for osteosarcoma. Read how the designation could accelerate development and create new investor interest.Biotech Co. Has Promising AI-Accelerated Pipeline
Research Report
Rakovina Therapeutics Inc. (RKV:TSX.V) recently gained analyst coverage from First Berlin Equity Research. Read on to see why this company rates the stock a Buy. Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results
Reviva Pharmaceuticals Holdings Inc. (RVPH: NASDAQ) is gaining attention with strong Phase 3 results for its lead CNS candidate, brilaroxazine. Here's what analysts are seeing in its long-term potential.Ascending Dose Trial of FABP5 Inhibitor to Read Out Soon
Research Report
Meanwhile, a representative from the company advancing the small molecule in the clinic is slated to speak about it at a conference this week, noted a D. Boral Capital report.